Key points from article :
Revel Pharmaceuticals raised $8.4M in Seed financing to advance its repair-based enzyme therapy pipeline towards the clinic.
Reimagining how enzymes can be used as therapeutics by developing repair based approaches to aging and disease.
One root cause of aging are the toxic chemical byproducts of metabolism that build up on the long-lived collagen proteins.
Toxic byproducts result in inflammation, stiffened tissues, high systolic BP, kidney damage, and increased risk of stroke and death.
Revel is developing designer enzymes to precisely remove and repair this damage from aging.
“Revel’s platform leverages nature’s chemical toolkit – enzymes – to repair collagen,” - Aaron Cravens, CEO at Revel Pharmaceuticals.
“Applying enzymes to repair decades of damage to collagen is a logical way to go about reversing age related disease,” - Cravens.
“Revel is leading innovation in repair-based approaches to aging”, - Patrick Burgermeister, board member of Revel Pharmaceuticals.
